Italy CAR-T Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Italy · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$130.8 MnPlaceholder estimate
Estimate 2025$161.3 Mn2.5% of the global market
Projected 2034$1.06 Bn 558.7%Adds $901.1 Mn over 9 forecast years
CAGR 2025–203423.3%Faster than 92% of 180 Pharmaceuticals markets here
44 in ItalySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Italy CAR-T Cell Therapy Market Analysis Executive Summary
CAR-T cell therapy changes a patient's own immune T cells so they can find and kill cancer cells, mainly in blood cancers.
Key segments of the CAR-T Cell Therapy market include target (CD19, BCMA and Others) and indication (Lymphoma, Leukemia and Multiple Myeloma).
Italy CAR-T Cell Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Italy CAR-T Cell Therapy Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the CAR-T Cell Therapy market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the CAR-T Cell Therapy market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for CAR-T Cell Therapy Market in Italy
The CAR-T Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for CAR-T Cell Therapy Market in Italy
CAR-T Cell Therapy in Italy: rules, payment and research
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.[2] ClinicalTrials.gov lists 44 studies on CAR-T Cell Therapy that are recruiting, active or about to start in Italy.[3]
[3]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for CAR-T Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Target
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Gilead Sciences (Kite)
7.2 Novartis
7.3 Bristol Myers Squibb
7.4 Johnson & Johnson
7.5 Legend Biotech
7.6 Autolus Therapeutics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The CAR-T Cell Therapy market can be segmented based on various criteria, including target, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in CAR-T Cell Therapy right now, from free public sources.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
World Bank.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
CAR-T Cell Therapy in context
Italy compared
Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]
[1]World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
How big is the CAR-T Cell Therapy market in Italy?
Placeholder estimate: about $161.3 Mn in 2025, rising to about $1.06 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the CAR-T Cell Therapy market in Italy growing?
Placeholder estimate: about 23.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the CAR-T Cell Therapy market report cover?
The report splits the market by target (CD19, BCMA, Others), indication (Lymphoma, Leukemia, Multiple Myeloma, Autoimmune Diseases) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the CAR-T Cell Therapy market?
Key players include Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and Autolus Therapeutics.
What is driving the CAR-T Cell Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.
Who regulates CAR-T Cell Therapy in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on CAR-T Cell Therapy are running in Italy?
44 studies are recruiting, active or about to start in Italy, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
How much research is published on CAR-T Cell Therapy?
PubMed lists 7,618 papers on CAR-T Cell Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Italy 
Germany
Russia
US
China
Canada
Japan
France
UK
Brazil
India
Saudi Arabia
Ecuador
Spain
Mexico
Australia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Fresenius SE & CO
Roche
AstraZeneca
Celltrion
Biogen Inc